الفهرس 
Introduction
Geographic variationOnly 14 pages are availabe for public view
 |  | from | 149 |  |  |
| | | from | 149 | | |
Abstract
In our study we compared safety, efficacy, feasibility and cost effectiveness of DEB-TACE versus combined c-TACE+PEI in the treatment of large HCC. 75 patients included in this study (30 patients were treated by combined c-TACE+PEI and 45 patients were treated by DEB-TACE), 59 Male (78.67%) and 16 (21.33) Female, Age of the patients enrolled in this study ranged from 47 to 86 years old.
By comparison of combined c-TACE+PEI group to DEB-TACE group results in our study, there was no significant difference in tumor response with better results in combined c-TACE+PEI group and significant difference in the Median value of the serum level of AFP after treatment between the two groups (p-value = 0.036).
Post embolization syndrome was more in DEB-TACE group than combined c-TACE+PEI with no significant difference. Major complications occurred in our study in the form of acute hepatic decompensation (10.66%), liver cell failure (10.66%), portal vein thrombosis (1.33%), hepatic encephalopathy (9.33%) showed no statistically significant difference between the two groups and no reported deaths during the period of the study.
There were no significant predictors for improving the response of the treatment in our study by using multivariate logistic regression analysis for all studied factors.
Cost effectiveness analyses recommend use of combined c-TACE+PEI (less cost) in the treatment of large HCC.